Advanced search
Start date
Betweenand

Development and evaluation of INSAF-HAS: a form to select patients for insertion into a pharmaceutical care service

Grant number: 11/00985-1
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): July 01, 2011
Effective date (End): September 30, 2014
Field of knowledge:Health Sciences - Pharmacy
Principal researcher:Leonardo Régis Leira Pereira
Grantee:Beatriz Maria Pereira Girolineto
Home Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Hypertension is a chronic disease in which blood pressure remains above 140/90 mmHg. It affects approximately 70 million people in the United States and 1 billion people worldwide (ONG et al, 2007). This disease may lead to complications, such as, we can highlight acute myocardial infarction and stroke. Studies have shown that pharmaceutical care can help to achieve important clinical outcomes, such as reduced blood pressure (ERICKSON; SLAUGHTER; HALAPY, 1997; ZILLICH et al 2005). However limited resources hinder the assurance of an appropriate pharmaceutical service to every patient who uses drugs. Therefore this study aims to develop and evaluate a form for selection of hypertensive patients and inclusion of these patients into a pharmaceutical care service as well as analyzing the effectiveness of this service during the follow-up period and after discharge. This study was divided into four phases, namely: development of the INSAF-HAS phase, selection phase, follow-up phase, and discharge phase. Subjects were divided according to the score obtained in the form (G1 - highest score, G2 - lowest score). Patients in each group were randomized into two groups, namely, Control (C) and Experimental (E), so we obtained a total of four groups (G1C, G1E, G2C, G2E). By the way subjects in experimental groups were included in a pharmaceutical care service and followed-up at monthly visits for twelve months. We found higher age, lower education, higher systolic blood pressure and fasting glucose, slightest knowledge on the medical treatment in Group 1 than Group 2. At the end of follow-up phase it was found lowering blood pressure in G1E and reduction in BMI, increased adherence to drug therapy and knowledge relating to drug therapy at G2E. In the discharge phase there was increased BP in all groups, but evidence was not observed that this increase was significant. Thus, it could be conclude that the instrument was appropriate for screening individuals for a pharmaceutical care service, and the pharmaceutical care service promoted clinical improvement in hypertensive patients. Even so new studies about the discharge are required.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
BEATRIZ MARIA PEREIRA GIROLINETO; ALAN MAICON DE OLIVEIRA; ANA MARIA ROSA FREATO GONÇALVES; MARÍLIA SILVEIRA DE ALMEIDA CAMPOS; LEONARDO RÉGIS LEIRA PEREIRA. INSAF-HAS: a tool to select patients with hypertension for pharmaceutical care. Einstein (São Paulo), v. 18, p. -, 2020.
PEREIRA GIROLINETO, BEATRIZ MARIA; DE OLIVEIRA, ALAN MAICON; ROSA FREATO GONCALVES, ANA MARIA; DE ALMEIDA CAMPOS, MARILIA SILVEIRA; LEIRA PEREIRA, LEONARDO REGIS. INSAF-HAS: a tool to select patients with hypertension for pharmaceutical care. Einstein (São Paulo), v. 18, 2020. Web of Science Citations: 0.
Academic Publications
(References retrieved automatically from State of São Paulo Research Institutions)
GIROLINETO, Beatriz Maria Pereira. Development and evaluation of INSAF-HAS: a form to select patients for insertion into a pharmaceutical care service. 2015. Doctoral Thesis - Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas de Ribeirão Preto Ribeirão Preto.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.